glp-1 for weight loss without diabetes and Beyond Weight Loss: ED Implications

We will cover this in the LA lesson

Notably, statistics reveal that approximately 40% of patients taking semaglutide reported no heavy drinking days, compared to just 20% in the placebo group, highlighting the potential benefits of this therapy in relation to alcohol and GLP-1

According to a 2017 systematic review in the Journal of Clinical Nursing confirming that aspiration before subcutaneous injection does not reduce adverse events, subcutaneous injections carry a distinct pharmacokinetic profile that intramuscular delivery disrupts, which is why correct angle and depth matter for predictable results

The off-period gives baseline NNMT activity a chance to reset before the next cycle